Biosense Webster/Stereotaxis ablation combination
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Biosense Webster's NaviStar and Celsius RMT steerable tip diagnostic/ablation catheters, approved for use with Stereotaxis' Niobe magnetic navigation system by FDA Feb. 7, will enable doctors "to steer a catheter remotely, map the electrical activity of the heart and ablate targeted areas" in patients with cardiac arrhythmias, according to the firm. Stereotaxis has touted its device as bringing value to complex cardiology and electrophysiology interventions (1"The Gray Sheet" Sept. 27, 2004, p. 12)...
You may also be interested in...
Cardiology Magnet May Prove Attractive To Other Procedures – Stereotaxis
Stereotaxis'Niobe magnetic navigation system will deliver therapeutic benefits to previously unaddressed areas of interventional cardiology, the firm anticipates
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.